DiaSorin's Growth Driven by COVID-19 Diagnostics, Other Tests Still Tracking Below Baseline

DiaSorin is a niche player in the fragmented in vitro diagnostic market with diagnostic specialization in infectious diseases. Its systems are able to perform niche testing for diseases such as hepatitis, tuberculosis, Zika virus, and measles. The firm maintains an 18% market share in immunodiagnostics and a 12% share in the highly competitive molecular diagnostics market. Despite operating in a competitive industry with high research requirements, DiaSorin has consistently been able to expand its installed base and deliver moatworthy returns for shareholders over time.